BNTC: Benitec Biopharma Inc. Stock

by  •  • Comments Off on BNTC: Benitec Biopharma Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 304.63
Enterprise Value ($M) 226.35
Book Value ($M) 75.94
Book Value / Share 3.24
Price / Book 4.01
NCAV ($M) 75.59
NCAV / Share 3.22
Price / NCAV 4.03

Profitability (mra)
Return on Invested Capital (ROIC) -0.28
Return on Assets (ROA) -1.00
Return on Equity (ROE) -1.38

Liquidity (mrq)
Quick Ratio 25.48
Current Ratio 25.48

Balance Sheet (mrq) ($M)
Current Assets 78.71
Assets 79.07
Liabilities 3.13
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -22.49
Net Income -21.75
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -19.40
Cash from Investing -0.18
Cash from Financing 68.03

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-14 13G/A Janus Henderson Group Plc 11.30 -2.82
02-13 13G/A HBM Healthcare Investments (Cayman) Ltd. 4.50 0.00
01-27 13G/A Franklin Resources Inc 18.10
11-18 13D/A Suvretta Capital Management, Llc 49.90 62.30
11-14 13G Nantahala Capital Management, LLC 9.65
04-11 13G/A Adage Capital Partners Gp, L.l.c. 9.99 39.81
2024-02-14 13G/A Citadel Advisors Llc 3.60

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-02-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2024 ☐ TRANSITION REPOR
2024-11-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPO
2024-09-26 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended June 30, 2024 ☐ Transition Report under Sect
2024-05-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT P

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-03-10 5,086 16,354 31.10
2025-03-07 6,997 25,584 27.35
2025-03-06 10,405 41,803 24.89
2025-03-05 3,210 20,504 15.66

(click for more detail)

Similar Companies
BGM – BGM Group Ltd. BIVI – BioVie Inc.
BMRA – Biomerica, Inc. BOLT – Bolt Biotherapeutics, Inc.
BON – Bon Natural Life Limited


Financial data and stock pages provided by
Fintel.io